Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Receivables: 2022-2025

Historic Receivables for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to $46,430.

  • Addex Therapeutics' Receivables fell 93.19% to $46,430 in Q2 2025 from the same period last year, while for Jun 2025 it was $708,721, marking a year-over-year decrease of 53.76%. This contributed to the annual value of $26,690 for FY2024, which is 84.15% down from last year.
  • Per Addex Therapeutics' latest filing, its Receivables stood at $46,430 for Q2 2025, which was up 18.05% from $39,330 recorded in Q1 2025.
  • Addex Therapeutics' 5-year Receivables high stood at $681,642 for Q2 2024, and its period low was $26,803 during Q4 2024.
  • Its 3-year average for Receivables is $326,655, with a median of $340,269 in 2023.
  • Per our database at Business Quant, Addex Therapeutics' Receivables surged by 41.03% in 2024 and then tumbled by 93.19% in 2025.
  • Over the past 4 years, Addex Therapeutics' Receivables (Quarterly) stood at $557,288 in 2022, then crashed by 69.40% to $170,533 in 2023, then crashed by 84.28% to $26,803 in 2024, then crashed by 93.19% to $46,430 in 2025.
  • Its Receivables stands at $46,430 for Q2 2025, versus $39,330 for Q1 2025 and $26,803 for Q4 2024.